INTRODUCTION

Venous thromboembolism (VTE) is the most common preventable cause of in-hospital death. However, the risk of VTE and prophylaxis practices in Polish hospitals are not known.

OBJECTIVES

The ENDORSE study in Poland was part of the global cross-sectional Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting survey with the objective to assess the prevalence of VTE risk in acutely ill medical and surgical patients and to determine the proportion of at-risk patients who receive recommended prophylaxis.

PATIENTS AND METHODS

In 10 non-academic Polish hospitals, a chart review was performed in all inpatients aged 40 or older admitted to medical wards, and in patients at the age of ≥18 admitted to surgical wards. The VTE risk and recommended prophylaxis were assessed according to the 2004 American College of Chest Physicians (ACCP) guidelines.

RESULTS

The study enrolled 2673 patients (1092 in surgical wards, 1581 in medical wards). Out of these, 1111 were judged to be at risk for VTE (597 surgical patients, 514 medical patients). Only 51.8% of all at-risk patients received ACCP-recommended VTE prophylaxis (54.7% of surgical patients, 32.5% of medical patients).

CONCLUSIONS

In Polish hospitals more than 40% of patients hospitalized for acute illness are at risk of VTE, but only a small proportion of them receives appropriate prophylaxis. These results call for decisive actions to ensure that at-risk patients receive recommended VTE prophylaxis.

KEY WORDS

ENDORSE study, Poland, venous thromboembolism, venous thromboembolism prophylaxis, venous thromboembolism risk factors

ABSTRACT

INTRODUCTION

Many surgical and medical inpatients are at markedly increased risk of venous thromboembolism (VTE). Such patients often have more than one risk factor for VTE, and these factors are usually combined. Approximately 5–10% of all deaths in hospitalized patients are accounted for by pulmonary embolism making VTE the most common preventable cause of in-hospital death.1,2 There are over 370,000 estimated VTE-related deaths per year in 6 European Union (EU) countries; 75% of them from hospital-acquired VTE.3 Extrapolation of American data indicates that in Poland pulmonary embolism may account annually for up to 25,000–33,000 deaths.4 Deep vein thrombosis and its long-term complications (post-thrombotic syndrome, chronic thromboembolic pulmonary hypertension) contribute to increased long-term patient morbidity and raise the costs for public healthcare systems.5,6

Despite the availability of evidence-based consensus guidelines1,7 thromboprophylaxis is often not implemented, due to underestimation of the risk or variable risk of hemorrhagic complications related to antithrombotic agents. Several epidemiologic studies have addressed the problem in defined countries and institutions outside Poland.8-10 Such studies have not been published in Poland yet.

Until now global data on the proportion of at-risk inpatients who should receive thromboprophylaxis have been unavailable. Recently,
For inclusion, each patient had to be hospitalized in an eligible ward on the predetermined day of survey. In large hospitals it was possible to survey one ward or floor on any particular day. Patients aged ≥40 years in eligible medical wards, or ≥18 years in eligible surgical wards were screened. The assessment of VTE risk (according to the 2004 ACCP guidelines) included acutely ill medical patients, patients hospitalized for major trauma or undergoing a major surgical procedure requiring general or epidural anesthesia for at least 45 minutes. Following the 2004 ACCP guidelines, surgical patients were classified as being at highest, high, moderate or low risk for VTE.

Only information about types of venous thromboprophylaxis included in the ACCP guidelines recommendations was collected, and only these types were taken into account for ACCP compliance determination. Anticoagulant prophylaxis was considered contraindicated if the patient presented with or developed during hospitalization any of the following: intracranial hemorrhage, liver impairment, bleeding at hospital admission, an active peptic ulcer, bleeding disorders of a known cause.

Cohen et al. published the results of the multinational, observational, cross-sectional ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) study, conducted between August, 2006 and January, 2007. The study assessed the number of patients at risk for VTE in the acute care hospital setting in 358 hospitals across 32 countries on 6 continents and established the proportion of patients who received thromboprophylaxis according to the recommendations of the American College for Chest Physicians (ACCP) guidelines. Poland took part in this study. This paper presents the country-specific data from 10 Polish hospitals participating in the ENDORSE study.

PATIENTS AND METHODS  Detailed procedures have been described in the primary ENDORSE report. Briefly, hospitals with >50 beds, admitting patients with acute medical illnesses and exacerbations of chronic diseases, and scheduled routine major surgical procedures were included in the study. In Poland, 10 non-academic hospitals were randomly selected from the Polish Hospital Register. According to the national rules, the approval of the Ethics Committee (Chamber of Physicians, Kraków) was obtained for the study in Poland. Signed patient consent was not required. Patients’ data, including demographics, admission and post-admission diagnoses, risk factors associated with VTE, bleeding risk factors for, the duration of a stay and the type of VTE prophylaxis, were collected from a review of hospital charts on standard case report forms by trained physicians.

For inclusion, each patient had to be hospitalized in an eligible ward on the predetermined day of survey. In large hospitals it was possible to survey one ward or floor on any particular day. Patients aged ≥40 years in eligible medical wards, or ≥18 years in eligible surgical wards were screened. The assessment of VTE risk (according to the 2004 ACCP guidelines) included acutely ill medical patients, patients hospitalized for major trauma or undergoing a major surgical procedure requiring general or epidural anesthesia for at least 45 minutes. Following the 2004 ACCP guidelines, surgical patients were classified as being at highest, high, moderate or low risk for VTE. Only information about types of venous thromboprophylaxis included in the ACCP guidelines recommendations was collected, and only these types were taken into account for ACCP compliance determination. Anticoagulant prophylaxis was considered contraindicated if the patient presented with or developed during hospitalization any of the following: intracranial hemorrhage, liver impairment, bleeding at hospital admission, an active peptic ulcer, bleeding disorders of a known cause.

Statistical analysis  Statistical analyses are discussed in detail in the global primary ENDORSE report. Briefly, quantitative data were presented as median, and the number of non-missing data. Categorical data were given as the number and percentage of the population. The SAS version 9.1 was used for all statistical analyses.
time to identify and enroll the eligible patients was 6 days.

The median age of patients in medical wards was 73 years and in surgical wards 62 years. The patient's characteristics and causes of hospitalization are shown in TABLE 1.

Risk factors for VTE that were present before hospital admission are shown in TABLE 2. Chronic heart failure was the most common VTE risk factor before admission both in medical and surgical patients (46.3% and 10.3%, respectively). The second most frequent VTE risk factor in medical patients was chronic pulmonary disease (24.4%) and in surgical patients varicose veins/venous insufficiency (7.9%). The most common post-admission risk factor for VTE in both medical and surgical patients was complete immobilization, followed by immobilization with bathroom privileges for surgical patients, and admission to an intensive or critical care unit in medical patients (TABLE 2).

Risk factors for bleeding were more common in medical than surgical patients. This risk in medical patients was mainly due to aspirin use and significant impairment of renal function, while in surgical patients the bleeding risk was due to use of non-steroidal anti-inflammatory drugs (TABLE 3).

RESULTS In the global ENDORSE study1, a total number of 68,183 patients were enrolled from 358 hospitals across 32 countries (Algeria, Australia, Bangladesh, Brazil, Bulgaria, Colombia, Czech Republic, Egypt, France, Germany, Greece, Hungary, India, Ireland, Kuwait, Mexico, Pakistan, Poland, Portugal, Romania, Russia, Saudi Arabia, Slovakia, Spain, Switzerland, Thailand, Tunisia, Turkey, United Arab Emirates, UK, USA, and Venezuela). Out of this number, 30,827 (45%) of the eligible patients were categorized as surgical and 37,356 (55%) as medical. According to the ACCP criteria, 35,329 (51.8%; between country range 35.6–72.6) patients were at risk for VTE, including 19,842 (64.4%; 44.1–80.2) surgical patients and 15,487 (41.5%; 21.1–71.2) medical patients. Of the surgical patients at risk, 11,613 (58.5%; 0.2–92.1) received ACCP-recommended VTE prophylaxis, compared with 6,119 (39.5%; 3.1–70.4) at-risk medical patients.

In Poland, a total number of 2,673 patients were enrolled from 10 hospitals, 1,092 (40.9%) on surgical and 1,581 (59.1%) on medical wards. The total number of beds assessed, together with reasons for exclusion, and the number of analyzed medical and surgical patients are shown in FIGURE 1. The median number of beds per hospital was 369.4 (range 233–565 beds). The median

| Patient characteristics                  | Surgical risk (n = 597) | Medical risk (n = 514) | All risk (n = 1111) |
|-----------------------------------------|------------------------|-----------------------|---------------------|
| Male                                    | 289 (49.7)             | 256 (51.2)            | 545 (50.4)          |
| Female                                  | 292 (50.3)             | 244 (48.8)            | 536 (49.6)          |
| Age (years)*                            | 62                     | 73                    | 68                  |
| BMI (kg/m²)*                            | 26.1                   | 27.5                  | 26.5                |
| Hospital admission to survey day (days)*| 6                      | 7                     | 6                   |

| Reason for hospitalization              | Surgical risk (n = 597) | Medical risk (n = 514) | All risk (n = 1111) |
|-----------------------------------------|------------------------|-----------------------|---------------------|
| Acute heart failure (NYHA class III/IV) | 8 (1.3)                | 176 (34.2)            | 184 (16.6)          |
| Other cardiovascular disease            | 80 (13.4)              | 155 (30.2)            | 235 (21.2)          |
| Ischemic stroke                         | 2 (0.3)                | 31 (6)                | 33 (3)              |
| Hemorrhagic stroke                      | 3 (0.5)                | 6 (1.2)               | 9 (0.8)             |
| Pulmonary infection                     | 9 (1.5)                | 186 (36.2)            | 195 (17.6)          |
| Acute non-infectious respiratory disease| 9 (1.5)                | 93 (18.1)             | 102 (9.2)           |
| Rheumatologic or inflammatory diseases  | 6 (1.0)                | 3 (0.6)               | 9 (0.8)             |
| Hematologic disease                     | 3 (0.5)                | 21 (4.1)              | 24 (2.2)            |
| Malignancy (active)                     | 56 (9.4)               | 26 (5.1)              | 82 (7.4)            |
| Infection (non-respiratory)             | 21 (3.5)               | 22 (4.3)              | 43 (4.0)            |
| Neurologic                              | 12 (2)                 | 19 (3.7)              | 31 (2.8)            |
| Renal                                   | 14 (2.3)               | 45 (8.8)              | 59 (5.3)            |
| Endocrine/metabolic                     | 39 (6.5)               | 58 (11.3)             | 97 (8.7)            |
| Gastro-intestinal/hepatobiliary         | 65 (10.9)              | 31 (6)                | 96 (8.6)            |
| Other medical conditions                | 99 (16.6)              | 35 (7.0)              | 134 (12.1)          |

* Data are shown as a median.

Data are shown as number (percentage). Denominators may vary due to missing data.

Abbreviations: BMI – body mass index
Out of 2673 analyzed patients, 1111 (41.6%) were deemed as being at VTE risk. Among 1,092 patients on surgical wards (see **Figure 1**), 597 (54.7%) were deemed to be at VTE risk. Four-hundred four (67.7%) of these at risk patients received any VTE prophylaxis and 396 (66.3%) received ACCP-recommended prophylaxis. Among 1581 patients on medical wards (see **Figure 1**), 514 (32.5%) were deemed to be at risk of VTE. Out of these 514 patients, 239 (46.5%) received any VTE prophylaxis; 179 (34.8%) received ACCP-recommended prophylaxis. Altogether, in Poland, out of 1111 inpatients at VTE risk, 575 (51.8%) received ACCP-recommended prophylaxis.

There was a substantial difference between participating hospitals in terms of percentages of at-risk patients among all analyzed surgical (range from 39.3% to 100%) and medical (range from 15.5% to 45.6%) patients. Such a marked difference was also typical of the everyday practice of administering ACCP-recommended prophylaxis. Among 1581 patients on medical wards (see **Figure 1**), 514 (32.5%) were deemed to be at risk of VTE. Out of these 514 patients, 239 (46.5%) received any VTE prophylaxis; 179 (34.8%) received ACCP-recommended prophylaxis. Altogether, in Poland, out of 1111 inpatients at VTE risk, 575 (51.8%) received ACCP-recommended prophylaxis.

For comparison, the proportion of patients at risk for VTE and the use of ACCP-prophylaxis in the EU countries are shown in **Figure 2**. In EU countries, the proportion of hospitalized medical patients at VTE-risk ranged from 31% (Hungary) to 63% (France) and the proportion of patients receiving ACCP-recommended prophylaxis from 18% (Romania) to 70% (Germany). In surgical patients, these proportions were 55% (Greece) to 78% (France), and 55% (Portugal) to 92% (Germany), respectively.

Anticoagulant agents (mainly heparins) were used in Poland as the preferred mode of VTE prophylaxis (92.1% of medical patients and 99.2% of surgical patients who received the ACCP recommended prophylaxis), followed by antivitamins K and other anticoagulants (see **Table 4**). The use of mechanical prophylaxis (foot pump, graduated compression stockings, and intermittent pneumatic compression) was limited to surgical patients only (<2% of all prophylactic measures).

Contraindications to anticoagulant prophylaxis were observed in 6.4% of both surgical and medical patients.

**DISCUSSION** The ENDORSE is by far the largest cross-sectional study assessing VTE risk and thromboprophylaxis in the acute hospital care setting. On a global scale 358 hospitals across 32 countries completed the study. Out of 340 hospitals which provided characteristic data, 44% were categorized as academic. In all hospitals participating in the study the number of assessable patients approached 70 thousand. About 50% of them were deemed to be at risk for VTE (64.4% of surgical patients and 41.5% of medical patients). The ACCP-recommended prophylaxis was received only by about 50% of patients at risk of VTE (58.5% of surgical patients; 39.5% of medical patients).
Wide differences in everyday practice of VTE prophylaxis in patients deemed as being at risk suggest that in many Polish hospitals, despite availability of original evidence-based consensus guidelines and its national adaptations, the awareness of the risk of VTE in hospitalized patients is still insufficient. Efforts should be made to increase this awareness through vigorous educational actions and in-hospital alert systems.

Heparins were by far the most often used type of prophylaxis in Polish medical patients. Mechanical prophylaxis was not used. While heparins were even more often used in surgical patients, a few patients received mechanical prophylaxis, mainly graduated compression stockings. In general, proportions of the type of VTE prophylaxis used in Poland are similar to the global data, but the use of mechanical prophylaxis is lower. Similarly to the other European countries, low-molecular-weight heparins (LMWH) were the most frequent pharmacologic approach (nearly 100% of heparins used) whereas in the USA unfractionated heparin was more prevalent in this setting.

In Poland all 10 hospitals participating in the study were non-academic to better reflect average hospital practice. The percentages of patients at VTE risk receiving recommended prophylaxis were not different from the global data, they were however slightly lower than those in the neighboring Czech Republic and Slovakia, and much lower than in Germany, the leader in antithrombotic prophylaxis among all participating countries. Numbers of patients at risk were comparable.

This is the first published report on DVT prophylaxis in medical and surgical hospital patients in Poland. The only other available in Poland data come from the EPID registry. This survey performed in internal medicine wards from 64 hospitals has shown that among medical patients at VTE risk, 44% received antithrombotic prophylaxis. This is in agreement with the findings presented in the discussed study (46.5% of all medical patients at risk receiving any VTE prophylaxis).
FIGURE 2 Proportion of medical (A) and surgical (B) patients at-risk for VTE and proportion of at-risk patients receiving recommended prophylaxis in the EU countries, including Poland

In Poland, as in other countries, including the European ones, ACCP-recommended prophylaxis was more often used in surgical than in medical patients. This is probably, at least in part, related to the clear VTE risk description for different types of surgical procedures included in the 2004 ACCP recommendations. There was no such risk categorization for medical patients in the ACCP guidelines. In the recently published 2008 ACCP guidelines medical patients are categorized into 2 groups. Fully mobile medical patients are considered as being of low (<10%) risk of deep-vein thrombosis (DVT) and do not require specific thromboprophylaxis, in contrast to bedridden or acutely-ill medical patients who are considered to be of moderate (10–40%) risk of DVT. Thromboprophylaxis options for the latter group include LMWH, unfractioned heparin or fondaparinux administration. Low rates of VTE prophylaxis in acutely-ill medical patients at high risk of VTE has been described in the past.

The ENDORSE study on Polish patients has several limitations. The first, and the most important, is the hospital (and consequently, patients) sample size. In Poland, a country with 40 million inhabitants and over 700 hospitals, even a random choice of ten hospitals might be too low to be fully representative. However, the wide variation of the everyday practice in implementing VTE prophylaxis with even the highest numbers being far from ideal are a sufficient argument for a "call to action". Secondly, some inaccuracies might have been introduced during data collection (one-day cross-sectional study), which however should not influence general conclusions. It is quite probable that the VTE risk factor was omitted rather than added in error. Thirdly, VTE prophylaxis could have been withheld due to the personal conviction of the attending physician that the risk of bleeding was high. Finally, survey awareness could have changed physicians’ behavior. Even then, they would probably have increased the use of prophylactic measures rather than withhold them.

In summary, results of the ENDORSE study in Poland show that, like in many other countries all over the world, VTE prophylaxis is underused in acutely ill medical and surgical inpatients. It seems that especially in medical patients the risk of VTE is substantially underestimated. Every effort should be made to increase awareness of VTE risk and ensure that at-risk patients receive appropriate prophylaxis through obligatory hospital alert systems and implementation of evidence-based guidelines. Widespread educational actions, among other things, could help achieve this aim.

ACKNOWLEDGMENTS The ENDORSE was an international study, supported by educational grant of Sanofi-Aventis (Paris, France) and coordinated by Prof. Frederic A. Anderson Jr., Center for Outcomes Research, University of Massachusetts Medical School, Worcester, MA, USA. We thank the physicians and study coordinators who participated in this study.

REFERENCES

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (Suppl 3): S338-S400.
2. Anderson FA, Zayanzyu M, Heit JA, et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007; 82: 777-782.
3. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated mortality and morbidity. Thromb Haemost. 2007; 98: 756-764.
4. Niżankowski R. [A commentary on “Guidelines for venous thrombotic embolic disease prophylaxis and treatment” (Med. Prakt. 5/2002, Suppl II)]. Med Prakt. 2002; 5: 100-101. Polish.
5. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997; 82: 423-428.
6. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004; 350: 2257-2264.
7. Nicolaidis AK, Fared J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006; 25: 100-101. Polish.
8. Otero R, Uresandi F, Cayuela A, et al. Use of venous thromboembolism prophylaxis for surgical patients: a multicentre analysis of practice in Spain. Eur J Surg. 2001; 167: 163-167.
9. Amin A, Sternkowski S, Lin J, et al. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost. 2007; 5: 1610-1616.
Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: Findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007; 132: 936-945.

Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008; 371: 387-394.

Kurzyna M, in behalf of the EPID register investigators. [Use of anti-thrombotic prophylaxis in Polish internal medicine departments – results of the EPID register]. InfoMedica, ed. 11th from November 18, 2004. Polish.

Zawilska K, Brożek J, Jaeschke R, et al. [Guidelines for venous thrombotic embolic disease prophylaxis and treatment. Update 2005]. Med Prakt. 2005; 5 (Suppl.). Polish.

[Venous thrombotic embolic disease prophylaxis and treatment: „Kon- sensus Polski” (Polish Consensus) 2008]. Acta Angiol. 2007; 13 (Suppl. C). Polish.

Goldhaber SZ. Preventing pulmonary embolism and deep vein thrombosis: a ‘call to action’ for vascular medicine specialists. J Thromb Haemost. 2007; 5: 1607-1609.

Rashid ST, Thruss MR, Razvi NA, et al. Venous thromboprophylaxis in UK medical inpatients. J R Soc Med. 2005; 98: 507-512.

Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133 (Suppl 6): S381-S453.

Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J. 2006; 332: 325-329.

Yu HT, Dylan ML, Lin J, et al. Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm. 2007; 64: 69-76.

LIST OF ENDORSE INVESTIGATORS IN POLAND
(number of the charts surveyed)

1 Wojewódzki Szpital Zespolony, Płock: Włodzimierz Klonowski (355)
2 ZOZ im. K. S. Wyszyńskiego, Sieradz: Zdzisław Prajs (279)
3 Regionalny Szpital Chorób Płuc, Szczecin: Marek Sell (240)
4 Szpital im. J. Dietla, Kraków: Andrzej Kosimia Kamyzy (235)
5 Radomski Szpital Specjalistyczny, Radom: Tadeusz Kalbarczyk (234)
6 Zakład Opieki Zdrowotnej Ministerstwa spraw Wewnętrznych, Olsztyn: Bartłomiej Biedziuk (180)
7 Szpital Wojewódzki, Opole: Józef Wysota (180)
8 Specjalistyczny Szpital im. E. Szczekliką, Tarnów: Marcin Kuta (168)
9 Wojewódzki Szpital Specjalistyczny, Wrocław: Wojciech Witkiewicz (168)
10 Szpital Biełąński, Warszawa: Ryszard Gellert (147)